{Seattle}, Washington — November 11, 2025 — Leads & Copy —Omeros Corporation (NASDAQ: OMER) will release its financial results for the quarter ending September 30, 2025, on Thursday, November 13, 2025, after the market closes.
Omeros management will host a conference call and live webcast on that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results, recent developments, and highlights.
To access the live webcast, visit Omeros’ website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, register at this link to receive a unique PIN. Once registered, dial into the conference line provided using the PIN or choose the “Call Me” option. If you lose your PIN, re-register to receive a new one.
A replay of the call will be accessible online at https://investor.omeros.com/archived-events.
Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications. The company focuses particularly on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Omeros’ lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is under regulatory review by the U.S. FDA and the European Medicines Agency for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.
OMS1029, a long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Zaltenibart (OMS906), Omeros’ MASP-3 inhibitor, is in clinical development for PNH and C3 glomerulopathy. According to a recently announced agreement, Novo Nordisk will acquire global rights to zaltenibart, including associated intellectual property and related assets.
Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, fully funded by the National Institute on Drug Abuse, as well as a growing portfolio of novel molecular and cellular therapeutic programs for oncology.
For more information, visit www.omeros.com.
Source: Omeros Corporation
